



May 1, 2025

First Choice Next Formulary Stelara Biosimilar Medications

The FDA has recently approved several biosimilars for Stelara(ustekinumab). All biosimilars are FDA approved for the same indications as branded Stelara. Stelara will be removed from the First Choice Next formulary as of **5/9/2025**. The following Stelara biosimilar medications will be added to the formulary at Tier 4 and require a prior authorization:

Proprietary	Non-proprietary	
Name	name	Interchangeability with Stelara
Steqeyma	(ustekinumab-stba)	N
Yesintek	(ustekinumab-kfce)	N
Otulfi	(ustekinumab-aauz)	N
Selarsdi	(ustekinumab-aekn)	Υ

Please note that Selardsi is interchangeable with Stelara. All biosimilars, including Selardsi require a new prescription. A prescription for Stelara cannot be used to fill a biosimilar product even if it is interchangeable.

Please assess and if clinically appropriate, consider the use of one of the above biosimilars in place of branded Stelara for your patients in the future. If you have any questions, please reach out to First Choice Next Pharmacy Services at 1-833-779-7229.

Thank you,

Pharmacy Services First Choice Next

AmeriHealth Caritas Next and First Choice Next are individual and family health plans offered both on and off the Health Insurance Marketplace® by certain companies within the AmeriHealth Caritas Family of Companies. AmeriHealth Caritas Next is offered by AmeriHealth Caritas VIP Next, Inc. in Delaware; AmeriHealth Caritas Florida, Inc. in Florida; AmeriHealth Caritas North Carolina, Inc. in North Carolina; and First Choice Next by Select Health of South Carolina, Inc. in South Carolina.